PTC Therapeutics Beats Q2 Estimates; Veracyte Posts 15% Revenue Surge, Raises FY26 Guidance
SentiSense · Published · Updated
PTC Therapeutics reported Q2 earnings that beat estimates. Veracyte also performed well, posting a 15% revenue surge and increasing fiscal year 2026 g...
Sign in to read the full story. Free accounts include 20 full reads a month.
Powered by SentiSense - Intelligent Market Analysis